The current landscape of the life sciences industry is hampered by constant change. Uncertainty exists around the potential implications of Brexit and international government administrations. Enhanced levels of public scrutiny are affecting organisation's corporate reputation and more complex negotiations with healthcare payors are required due to a patient centred approach that is now focused on overall outcomes. Organisations within the life sciences industry are also changing, with many blue chip companies opting to consolidate specific markets through Mergers and Acquisitions (M&A) or restructuring their own organisation.
At Grant Thornton we combine strategic thinking and leverage our global expertise to deliver practical management solutions while cognisant of the local and international climate.